Nine Catalysts For China Biopharma In 2019

After much turmoil in 2018, the biopharma sector in China is embracing multiple uncertainties in the year of the boar.

Shanghai overpass
Shanghai Leads China's Massive "4+7" Centralized Bidding Scheme. • Source: Shutterstock

What's in store for the biopharma sector in China in 2019? Scrip has picked the following nine trends, from AI to vaccines, from supplementary products to generic drugs, to help you navigate the country's increasingly complex and volatile market.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

More from Focus On Asia